Insight Genetics Receives NCI Grant for Lung Cancer Test

By Bio-IT World Staff  

 

January 9, 2014 | Insight Genetics has received a new $1.5 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI), their sixth contract from NCI for companion diagnostics development. 

 

The new contract will allow the company to continue its development of Insight ALK Resistance, a diagnostic test that helps clinicians monitor their non-small cell lung cancer (NSCLC) patients for resistance to their prescribed cancer therapy. The test was previously developed under a Phase 1 NCI award. 

 

“Resistance is a growing concern in the cancer treatment world,” said Eric Dahlhauser, Chairman and CEO of Insight Genetics in a statement. “The Insight ALK Resistance assay meets a significant unmet need in non-small cell lung cancer by giving physicians a way to monitor their patients for drug resistance and providing information to help them determine the most effective course of treatment. Our team is delighted to continue our collaboration with the NCI to create companion diagnostic tests that can enhance how cancer is diagnosed, treated and monitored.”

 

Targeted therapeutics have been developed that effectively inhibit known genetic drivers of NSCLC such as EGFR and anaplastic lymphoma kinase (ALK). However, most patients develop resistance to their prescribed inhibitor within a year, making it no longer effective. Inhibitor resistance is driven by mutations in either the primary oncogenic gene or a separate gene in a secondary pool of cancer cells. Identification of the genetic driver of a patient’s inhibitor resistance can help a physician choose the appropriate ongoing treatment for the patient, which could include a next-generation inhibitor or other therapy that targets a separate oncogenic driver.

 

Insight ALK Resistance is a qPCR-based test that is customizable to detect all clinically identified resistance mutations in the ALK kinase domain or specific mutations, providing results within 48 hours and with minimal tissue requirement. The test can be used for various applications, including providing guidance in monitoring treatment efficacy, clinical decision making for alternative treatments, clinical trial enrollment for next-generation ALK inhibitors, or investigational academic research. Insight Genetics has obtained an exclusive worldwide license from St. Jude Children’s Research Hospital for the detection of ALK inhibitor resistance mutations.

 

Insight ALK Resistance is currently offered by Insight Molecular Labs, the CLIA-certified subsidiary of Insight Genetics, as a laboratory-developed test. Insight Molecular Labs provides support services for clinical trials on targeted therapeutics, including the identification of appropriate patients for trials, and specializes in the detection and monitoring of molecular-driven drug resistance in patients being treated with specific cancer therapies.